Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: sewastianik t. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P. Szydlowski M, et al. Among authors: sewastianik t. Blood. 2016 Feb 11;127(6):739-48. doi: 10.1182/blood-2015-06-654111. Epub 2015 Nov 19. Blood. 2016. PMID: 26585955 Free article.
Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice.
Sewastianik T, Jiang M, Sukhdeo K, Patel SS, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus GS, Rich JN, Weinstock DM, Mullighan CG, Sharpless NE, Carrasco RD. Sewastianik T, et al. Blood Adv. 2017 Nov 21;1(25):2361-2374. doi: 10.1182/bloodadvances.2017012211. eCollection 2017 Nov 28. Blood Adv. 2017. PMID: 29296886 Free PMC article.
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.
Guimarães PPG, Gaglione S, Sewastianik T, Carrasco RD, Langer R, Mitchell MJ. Guimarães PPG, et al. Among authors: sewastianik t. ACS Nano. 2018 Feb 27;12(2):912-931. doi: 10.1021/acsnano.7b05876. Epub 2018 Feb 6. ACS Nano. 2018. PMID: 29378114 Free PMC article. Review.
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.
McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr. McBrayer SK, et al. Among authors: sewastianik t. Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13. Cell. 2018. PMID: 30220459 Free PMC article.
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T, Guerrera ML, Adler K, Dennis PS, Wright K, Shanmugam V, Huang Y, Tanton H, Jiang M, Kofides A, Demos MG, Dalgarno A, Patel NA, Nag A, Pinkus GS, Yang G, Hunter ZR, Jarolim P, Munshi NC, Treon SP, Carrasco RD. Sewastianik T, et al. Blood Adv. 2019 Nov 12;3(21):3360-3374. doi: 10.1182/bloodadvances.2019000588. Blood Adv. 2019. PMID: 31698464 Free PMC article.
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
Castillo JJ, Libby EN, Ansell SM, Palomba ML, Meid K, Flynn CA, Leventoff C, Hergott CB, Sewastianik T, Morgan EA, Carrasco R, Fromm JR, Yang G, Hunter Z, Treon SP. Castillo JJ, et al. Among authors: sewastianik t. Blood Adv. 2020 Oct 27;4(20):5089-5092. doi: 10.1182/bloodadvances.2020003087. Blood Adv. 2020. PMID: 33085756 Free PMC article. Clinical Trial.
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.
Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. Lazarian G, et al. Among authors: sewastianik t. Cancer Cell. 2021 Mar 8;39(3):380-393.e8. doi: 10.1016/j.ccell.2021.02.003. Cancer Cell. 2021. PMID: 33689703 Free PMC article.
28 results